TY - JOUR
T1 - Patterns of Perceived Stress Throughout the Migraine Cycle
T2 - A Longitudinal Cohort Study Using Daily Prospective Diary Data
AU - Vives-Mestres, Marina
AU - Casanova, Amparo
AU - Buse, Dawn C.
AU - Donoghue, Stephen
AU - Houle, Timothy T.
AU - Lipton, Richard B.
AU - Mian, Alec
AU - Shulman, Kenneth J.
AU - Orr, Serena L.
N1 - Funding Information:
Marina Vives‐Mestres has received consulting fees from Curelator Inc. and holds stock options in Curelator Inc. Amparo Casanova has received consulting fees from Curelator Inc. and holds stock options in Curelator Inc. Dawn C. Buse, PhD, in the past 12 months, has received grant support from NIH/FDA and Amgen. She has received compensation for consulting from Allergan, Amgen, Avanir, Biohaven, Lilly, Promius, and Teva. She holds stock with Unison Mind. She is on the editorial board of . Stephen Donoghue receives consulting fees from and has stock options in Curelator Inc. Timothy T. Houle has received grant support from the NIH. He has received compensation for consulting from GlaxoSmithKline and Lilly. He serves as the Statistical Editor for Anesthesiology and Statistical Consultant for Headache. He is a Chief Scientist at StatReviewer. Richard B. Lipton receives research support from the NIH: 2PO1 AG003949 (mPI), 5U10 NS077308 (PI), R21 AG056920 (Investigator), 1RF1 AG057531 (Site PI), RF1 AG054548 (Investigator), 1RO1 AG048642 (Investigator), R56 AG057548 (Investigator), U01062370 (Investigator), RO1 AG060933 (Investigator), RO1 AG062622 (Investigator), 1UG3FD006795 (mPI), 1U24NS113847 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor), and K23 NS107643 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of , senior advisor to , and associate editor to . He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Allergan, American Headache Society, Amgen, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s (Promius), Electrocore, Eli Lilly, eNeura Therapeutics, Equinox, GlaxoSmithKline, Lundbeck (Alder), Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. He receives royalties from Wolff’s Headache 7 and 8 Edition, Oxford Press University, 2009, Wiley, and Informa. Alec Mian holds stock and holds stock options in Curelator Inc. Kenneth J. Shulman has received consulting fees from Curelator Inc. and holds stock options in Curelator Inc. Serena L. Orr receives royalties from Cambridge University Press. She serves on the editorial board of . She also has funding from the Alberta Children’s Hospital Research Institute. Conflict of Interest: Current Pain and Headache Reports Neurology Headache Cephalalgia th th Headache
Funding Information:
This study was supported by Curelator Inc, 210 Broadway, Cambridge, MA 02139, USA. Funding: rd
Publisher Copyright:
© 2020 American Headache Society
PY - 2021/1
Y1 - 2021/1
N2 - Objectives: To describe patterns of perceived stress across stages of the migraine cycle, within and between individuals and migraine episodes as defined for this study. Methods: Individuals with migraine aged ≥18 years, who were registered to use the digital health platform N1-HeadacheTM, and completed 90 days of daily data entry regarding migraine, headache symptoms, and lifestyle factors were eligible for inclusion. Perceived stress was rated once a day at the participant’s chosen time with a single question, “How stressed have you felt today?” with response options graded on a 0-10 scale. Days were categorized into phases of the migraine cycle: Ppre = pre-migraine headache (the 2 days prior to the first day with migraine headache), P0 = migraine headache days, Ppost = post-migraine headache (the 2 days following the last migraine day with migraine headache), and Pi = interictal days (all other days). Episodes, defined as discrete occurrences of migraine with days in all 4 phases, were eligible if there was at least 1 reported daily perceived stress value in each phase. Individuals with ≥5 valid episodes, and ≥75% compliance (tracking 90 days in 120 calendar days or less) were eligible for inclusion in the analysis. Results: Data from 351 participants and 2115 episodes were included in this analysis. Eighty-six percent of the sample (302/351) were female. The mean number of migraine days per month was 6.1 (range 2-13, standard deviation = 2.3) and the mean number of episodes was 6.0 (range 5-10, standard deviation = 1.0) over the 90-day period. Only 8 (8/351, 2.3%) participants had chronic migraine (defined as 15 or more headache days per month with at least 8 days meeting criteria for migraine). Cluster analysis revealed 3 common patterns of perceived stress variation across the migraine cycle. For cluster 1, the “let down” pattern, perceived stress in the interictal phase (Pi) falls in the pre-headache phase (Ppre) and then decreases more in the migraine phase (P0) relative to Pi. For cluster 2, the “flat” pattern, perceived stress is relatively unchanging throughout the migraine cycle. For cluster 3, the “stress as a trigger/symptom” pattern, perceived stress in Ppre increases relative to Pi, and increases further in P0 relative to Pi. Episodes were distributed across clusters as follows: cluster 1: 354/2115, 16.7%; cluster 2: 1253/2115, 59.2%, and cluster 3: 508/2115, 24.0%. Twelve participants (12/351, 3.4%) had more than 50% of their episodes fall into cluster 1, 216 participants (216/351, 61.5%) had more than 50% of their episodes fall into cluster 2, and 25 participants (25/351, 7.1%) had more than 50% of their episodes fall into cluster 3. There were 40 participants with ≥90% of their episodes in cluster 2, with no participants having ≥90% of their episodes in cluster 1 or 3. Conclusions: On an aggregate level, perceived stress peaks during the pain phase of the migraine cycle. However, on an individual and episode basis, there are 3 dominant patterns of perceived stress variation across the migraine cycle. Elucidating how patterns of perceived stress vary across the migraine cycle may contribute insights into disease biology, triggers and protective factors, and provide a framework for targeting individualized treatment plans.
AB - Objectives: To describe patterns of perceived stress across stages of the migraine cycle, within and between individuals and migraine episodes as defined for this study. Methods: Individuals with migraine aged ≥18 years, who were registered to use the digital health platform N1-HeadacheTM, and completed 90 days of daily data entry regarding migraine, headache symptoms, and lifestyle factors were eligible for inclusion. Perceived stress was rated once a day at the participant’s chosen time with a single question, “How stressed have you felt today?” with response options graded on a 0-10 scale. Days were categorized into phases of the migraine cycle: Ppre = pre-migraine headache (the 2 days prior to the first day with migraine headache), P0 = migraine headache days, Ppost = post-migraine headache (the 2 days following the last migraine day with migraine headache), and Pi = interictal days (all other days). Episodes, defined as discrete occurrences of migraine with days in all 4 phases, were eligible if there was at least 1 reported daily perceived stress value in each phase. Individuals with ≥5 valid episodes, and ≥75% compliance (tracking 90 days in 120 calendar days or less) were eligible for inclusion in the analysis. Results: Data from 351 participants and 2115 episodes were included in this analysis. Eighty-six percent of the sample (302/351) were female. The mean number of migraine days per month was 6.1 (range 2-13, standard deviation = 2.3) and the mean number of episodes was 6.0 (range 5-10, standard deviation = 1.0) over the 90-day period. Only 8 (8/351, 2.3%) participants had chronic migraine (defined as 15 or more headache days per month with at least 8 days meeting criteria for migraine). Cluster analysis revealed 3 common patterns of perceived stress variation across the migraine cycle. For cluster 1, the “let down” pattern, perceived stress in the interictal phase (Pi) falls in the pre-headache phase (Ppre) and then decreases more in the migraine phase (P0) relative to Pi. For cluster 2, the “flat” pattern, perceived stress is relatively unchanging throughout the migraine cycle. For cluster 3, the “stress as a trigger/symptom” pattern, perceived stress in Ppre increases relative to Pi, and increases further in P0 relative to Pi. Episodes were distributed across clusters as follows: cluster 1: 354/2115, 16.7%; cluster 2: 1253/2115, 59.2%, and cluster 3: 508/2115, 24.0%. Twelve participants (12/351, 3.4%) had more than 50% of their episodes fall into cluster 1, 216 participants (216/351, 61.5%) had more than 50% of their episodes fall into cluster 2, and 25 participants (25/351, 7.1%) had more than 50% of their episodes fall into cluster 3. There were 40 participants with ≥90% of their episodes in cluster 2, with no participants having ≥90% of their episodes in cluster 1 or 3. Conclusions: On an aggregate level, perceived stress peaks during the pain phase of the migraine cycle. However, on an individual and episode basis, there are 3 dominant patterns of perceived stress variation across the migraine cycle. Elucidating how patterns of perceived stress vary across the migraine cycle may contribute insights into disease biology, triggers and protective factors, and provide a framework for targeting individualized treatment plans.
KW - epidemiology
KW - migraine
KW - prodrome
KW - stress
UR - http://www.scopus.com/inward/record.url?scp=85090861042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090861042&partnerID=8YFLogxK
U2 - 10.1111/head.13943
DO - 10.1111/head.13943
M3 - Article
C2 - 32918830
AN - SCOPUS:85090861042
SN - 0017-8748
VL - 61
SP - 90
EP - 102
JO - Headache
JF - Headache
IS - 1
ER -